Expand all sections

Bardoxolone Methyl

Extended indication Chronic kidney disease
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Bardoxolone Methyl
Domain Metabolism and Endocrinology
Reason of inclusion New medicine (specialité)
Main indication Metabolic diseases
Extended indication Chronic kidney disease
Mechanism of action Antioxidant
Route of administration Oral
Therapeutical formulation Capsule

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date October 2021
Expected Registration November 2022
Orphan drug Yes
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet
References NCT03749447

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.